AVTX
Avalo Therapeutics, Inc.
Recent 8-K filings for AVTX
Each filing is summarized by an LLM — headline, three bullets, event type. The source document on EDGAR is one click away. See methodology.
-
May 13, 2026 11:00 UTC earnings item 2.02item 9.01
Avalo reports Q1 net loss $19.6M, Phase 2 HS trial meets endpoints, $431M offering
source · AVTX on sec.gov